GRI Bio, Inc. (GRI)

Market Cap	6.79M
Revenue (ttm)	n/a
Net Income (ttm)	-8.26M
Shares Out	8.93M
EPS (ttm)	-7.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,969
Open	0.790
Previous Close	0.777
Day's Range	0.755 - 0.800
52-Week Range	0.302 - 65.000
Beta	n/a
Analysts	Strong Buy
Price Target	11.50 (+1,413.16%)
Earnings Date	Nov 14, 2024

About GRI

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: GRI
• Website: https://www.gribio.com

Analyst Forecast

According to 2 analysts, the average rating for GRI stock is "Strong Buy." The 12-month stock price forecast is $11.5, which is an increase of 1,413.16% from the latest price.

Price Target

$11.5

(1,413.16% upside)

Analyst Consensus: Strong Buy